Navigation Links
Dartmouth awarded lead role in NCI clinical trials network
Date:4/24/2014

(Lebanon, NH, 4/24/14) Dartmouth has been awarded one of 30 grants from the National Cancer Institute (NCI) to serve as a Lead Academic Participating Site in its new National Clinical Trials Network (NCTN). Award recipients are a select groups of investigators charged with distributing resources in a more effective way across fewer cooperative groups.

The NCTN grant system reflects recommendations from a 2010 Institute of Medicine Report. It streamlines operations to achieve four goals:

  • Faster design, launch, and completion of clinical trials

  • Optimal use of scientific innovations

  • Strategic prioritization of studies

  • Expanded participation of patients and physicians

Through a consolidation of operational resources, the NCTN untangles behind-the-scenes red tape by using:

  • A common IT data management systems

  • One Central Institutional Review Board

  • Integrated specimen banks and informatics systems

Everyonepatients, providers, and family memberswants to see faster access to new treatments for cancer, said Konstantin H. Dragnev, MD, principal investigator for the Dartmouth-Hitchcock Norris Cotton Cancer Center site. This new framework will cut the startup time for a clinical trial by 75 percent in some cases. It removes obstacles we used to face for reporting and oversight, so we can now offer therapeutic advances to patients sooner.

As a Lead Academic Participating Site, Norris Cotton Cancer Center will be charged with enhancing participation in NCI randomized phase three clinical trials, the gold standard in cancer research for establishing new treatments for a five year period. Participating sites provide scientific leadership in the development of clinical trials, while meeting performance benchmarks for quality clinical research. Dartmouth will oversee involvement and participation from affiliated patient enrollment settings in New Hampshire, Vermont, and other states.

As a group we can achieve more than we can individually, said Dragnev of the co-operative groups in the nationwide network. Urban and rural residents can participate in the same study, which expands our ability to include a more diverse population in an individual study. The Dartmouth-led affiliations also mean greater access to new therapies in relatively remote areas served in northern New England.

The new network represents an unmatched effort to integrate and streamline the process of cancer clinical trials research, said James Doroshow, MD, deputy director for clinical and translational research at NCI. The conduct of NCI-supported trials, which are publicly funded, involves a complex system of designing, reviewing, and initiating studies. The new NCTN replaces a structure that was more than 55 years old.

NCTN employs an inclusive process for generating studies and conducting clinical trials using broad representation from the oncology field, including academic researchers, as well as professional organizations, patients, and advocates.

The Network has combined smaller cooperative groups with specialized foci, such as, pediatric, breast/bowel, or gynecological cancers. These consolidated cooperative groups allow for closer communication and collaboration among researchers doing work in the same area. The newly announced Lead Academic Participating Sites will serve as common outlets for offering trials originating from any of these groups.

Norris Cotton Cancer Centers selection as a Lead Participating Site affirms our role as a national leader in cancer research, said Mark Israel, MD, director, Norris Cotton Cancer Center. We are among an elite group of investigators conducting nationally the highest caliber of scientific research.
'/>"/>

Contact: Donna Dubuc
Donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert  

Related medicine news :

1. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
2. Dartmouth study provides first global evidence that foreign aid boosts public opinion
3. Dartmouth researcher finds novel genetic patterns that make us rethink biology and individuality
4. Clemson, Dartmouth use $1.5M grant to develop mobile health technology
5. Dartmouth researchers receive $5.9 million grant from NIH for lung research
6. Dartmouth researchers develop molecular switch that changes liquid crystal colors
7. Dartmouth researchers test safety of Nivolumab in kidney cancer
8. Leap in leukemia treatment reported by Dartmouth researchers
9. Dartmouth medical research closes in on new tuberculosis vaccine
10. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
11. Dartmouth researchers investigate the cognitive effects of athlete head impacts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dartmouth awarded lead role in NCI clinical trials network
(Date:3/28/2017)... ... 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader ... women’s hair loss. Although hair transplant procedures can be seen as more of a ... can be two reasons a woman may see her hair thinning. , “We are ...
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the ... , “There were things that his parents and teachers had asked of him that he ... he was going to defy the Almighty Creator. There were some who would have felt ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Bruce Trimble ... without requiring a referral. Trimble Dental offers a variety of services to ... dental implants. Whether patients have discolored, crooked or missing teeth in Eau Claire, ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the second major ... in 2014. It is the culmination of collaborative efforts by members of ... OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided key technical ...
(Date:3/27/2017)... Boston, MA (PRWEB) , ... March 27, 2017 ... ... NEJM Group, the organization behind the New England Journal of Medicine and NEJM ... , NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017  BERG, a biopharmaceutical company uncovering ... approach, today announced that the company,s Interrogative ... new data using a cold-induced model to ... Joslin Diabetes Center led the investigation with ... analysis of samples.  The findings were published ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... mixed colors as the NASDAQ Composite closed the trading ... 0.29% lower; and the S&P 500 was down 0.08%. ... of nine sectors finishing the day in green. Pre-market ... stocks: Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: